Literature DB >> 12170277

Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.

Michael J Asmus, Leslie Hendeles, Miles Weinberger, Richard C Ahrens, Hans Bisgaard, Jan Lötvall, Paul M O'Byrne, Donald W Cockcroft.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12170277     DOI： 10.1067/mai.2002.126375

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  5 in total

Review 1.  Single-enantiomer drugs: elegant science, disappointing effects.

Authors:  Peter Mansfield; David Henry; Anne Tonkin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

3.  Addition of levalbuterol to a pediatric emergency department automated medication management system does not increase its use.

Authors:  Gregory P Conners; Daniel P Hays; Thomas Richardson; Frank L Zwemer
Journal:  Int J Emerg Med       Date:  2009-12-11

Review 4.  6. Asthma.

Authors:  Robert F Lemanske; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 5.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.